Society of Hematologic Oncology Insider news

Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural SOHO UK meeting, scheduled for March 3–4, 2026, in London.

Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as findings from a large real-world evidence study of secondary CNS lymphoma.

She will also lead a session on peripheral T-cell lymphoma focused on the shift toward biologically informed therapy. The presentation will highlight the TERZO study and explore how emerging biologic insights may guide treatment decisions in this heterogeneous group of lymphomas.

The sessions are part of the program for the first SOHO UK meeting, which will bring together global clinicians and researchers to discuss advances in the treatment of blood cancers.

The second session of the Community Oncology Brown Bag Series, hosted by SOHO Insider, held on February 11, 2026, and featured guest speaker Tara Graff, DO, MS, at Mission Cancer + Blood and director of their clinical research program. Dr. Graff discussed “Moving CAR T-cell therapies into the community setting.”

This program is led by Loretta Nastoupil, MD, the SOHO Insider community oncology section editor.

To register for the series, go to https://soho.click/community-oncology-series

John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.

For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely topic as NIH funding continues to decline.

“SOHO 2026 will explore how public-private partnerships can sustain discovery, preserve basic research, and ensure access to innovation for patients around the world,” Dr. DiPersio said in a recent interview with SOHO Insider.

Register for SOHO 2026 today

Register today for SOHO 2026 at soho.click/2026. SOHO members receive a 40% discount. Join SOHO for free at http://soho.click/join.

In this episode of the SOHO Insider podcast, Andrew Kuykendall, MD, assistant member at Moffitt Cancer Center, and Douglas Tremblay, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discuss how to approach the treatment of essential thrombocythemia.

“The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk of thrombosis. There’s several different risk stratification methods, but they all rely on three clinical factors in general, which is age of prior thrombosis, which is probably the most potent risk factor.”

This episode also includes a discussion on the SURPASS-ET trial, which showed ropeginterferon alfa-2b outperformed anagrelide for disease control. Plus, a look into how new CALR-targeted antibodies improve bone marrow in early studies.



Dr. Masarova discusses SURPASS-ET study at EHA 2025

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase, an American father of two who was diagnosed with myeloma in 2014; Chase was the only American to travel to Nanjing, China, in 2017 to receive ciltacabtagene autoleucel (cilta-cel; then LCAR-B38M).

Chase shares his experience traveling to China for the therapy as a heavily-treated patient with limited treatment options. Chase talked about his treatment journey, his experience being treated in a foreign country with an experiment therapy, and what it was like achieving long-term remission.

Dr. Martin also discussed the five-year CARTITUDE-1 follow-up date presented at both ASCO(R) and EHA 2025. Those date showed that one-third of myeloma patients were in remission more than five years after cilta-cel treatment. The results of these trials and other trial data on therapies other than cilta-cel, prompted Sundar Jagannath, MD, during SOHO 2025 to address the potential of using the word cure when speaking with patients.